Direct to Smoker Outreach in a Health Care Setting (DTS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Tobacco use is the leading preventable cause of death in the United States. Effective treatment for tobacco dependence exists and includes counseling and pharmacotherapy with nicotine replacement, bupropion, or varenicline. The health care system is a key channel for delivering this treatment to smokers. Brief clinical interventions delivered at office visits increase smoking cessation rates, are among the most cost-effective of medical interventions, and are recommended by U.S. Public Health Service. However, physicians and other clinicians often fail to provide them. Clinicians' rates of providing tobacco treatment in ambulatory care can be improved, but even when successful, clinicians can only reach smokers who make an office visit.
A health care system might improve its delivery of tobacco treatment by supplementing visit-based efforts with a population-based strategy, using methods proven effective in public health settings. A population of smokers could be identified from electronic health records and offered treatment proactively in a way that maximizes convenience and minimizes barriers such the cost of pharmacotherapy. This study tests the effectiveness of a population-based Direct-to-Smoker (DTS) outreach program provided to smokers in one community health center in Revere, MA, that is part of an integrated health care system. It uses the system's population management tools to identify smokers and proactively offers them evidence-based tobacco treatment that is free and does require making an office visit. A randomized controlled trial will compare the effectiveness of the DTS program to usual primary care. The hypothesis is that adding the DTS program to usual primary care will increase the proportion of smokers who use tobacco dependence treatment and thereby stop smoking.
| Condition | Intervention |
|---|---|
|
Tobacco Dependence |
Other: Direct to Smoker Outreach Program |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A POPULATION-BASED DIRECT-TO-SMOKER OUTREACH OFFERING TOBACCO TREATMENT IN A HEALTH CARE SETTING: A RANDOMIZED CONTROLLED TRIAL |
- proportion of participants who reported using any tobacco dependence treatment during the 3-month study period [ Time Frame: 3 months ] [ Designated as safety issue: No ]Tobacco dependence treatment is defined as (1) any smoking cessation counseling contact (with the Tobacco Treatment Coordinator, the Massachusetts Smokers Quitline, or in-person counseling) or (2) any FDA-approved smoking cessation pharmacotherapy (nicotine patch, gum, lozenge, inhaler, or nasal spray; bupropion; or varenicline).
- 7-day point prevalence abstinence from tobacco products [ Time Frame: 3 month follow-up ] [ Designated as safety issue: No ]tobacco abstinence, defined as self-reported 7-day point prevalence abstinence at 3-month follow-up
- 30-day point prevalence abstinence from tobacco products [ Time Frame: 3 month follow-up ] [ Designated as safety issue: No ]Tobacco abstinence, defined as self-reported 30-day point prevalence abstinence at 3-month follow-up
- Use of nicotine replacement therapy [ Time Frame: Past 3 months ] [ Designated as safety issue: No ]Use of nicotine patch, gum, lozenge, inhaler, or nasal spray in the past 3 months.
- Use of any tobacco cessation medication [ Time Frame: Past 3 months ] [ Designated as safety issue: No ]Use of any nicotine replacement product, varenicline, or bupropion in the past 3 months in order to quit smoking
- Use of smoking cessation counseling [ Time Frame: Past 3 months ] [ Designated as safety issue: No ]Use of telephone or in-person smoking cessation counseling in the past 3 months
| Enrollment: | 590 |
| Study Start Date: | July 2009 |
| Study Completion Date: | July 2010 |
| Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: Usual clinical care
Usual clinical care provided by health care system
|
|
|
Experimental: DTS intervention
Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP that encourages the smoker to quit, and offers a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC), free nicotine patches, and referral to additional treatment resources including the state's free telephone quitline.
|
Other: Direct to Smoker Outreach Program
Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP, encouraging the smoker to quit, and offering a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC). Participants can respond to the treatment offer by calling or emailing the TTC, who will provide a 15-minute consultation following the "5A" strategy recommended by the US Public Health Service's clinical guideline and help smokers access treatment by (1) offering a free 4-week supply of 21mg nicotine patches sent by secure mailing to their home (refillable once for a total of 8 weeks), (2) helping smokers obtain prescriptions from their PCP for other FDA-approved smoking cessation medication, (3) using a fax-referral system to facilitate connection to free multi-session counseling from the Massachusetts Smokers Quitline, and (4) referring to local in-person counseling programs.
Other Name: Nicotine transdermal patch
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adults (>= 18 years)
- made an office visit to a primary care physician (PCP) at Revere Health Center in the year prior to May 2009
- has a telephone
- listed as a smoker in the past 5 years in the electronic health record
Exclusion Criteria:
- severe psychiatric or neurologic diagnosis (e.g., psychosis, dementia) on problem list of electronic health record
Contacts and Locations| United States, Massachusetts | |
| Revere Health Center | |
| Revere, Massachusetts, United States | |
| Principal Investigator: | Nancy A Rigotti, MD | Massachusetts General Hospital |
More Information
No publications provided by Massachusetts General Hospital
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Nancy Rigotti, Massachusetts General Hospital |
| ClinicalTrials.gov Identifier: | NCT01321944 History of Changes |
| Other Study ID Numbers: | 2009P001137 |
| Study First Received: | March 22, 2011 |
| Last Updated: | March 22, 2011 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Tobacco Use Disorder Substance-Related Disorders Mental Disorders Nicotine Ganglionic Stimulants Autonomic Agents Peripheral Nervous System Agents |
Physiological Effects of Drugs Pharmacologic Actions Nicotinic Agonists Cholinergic Agonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on June 18, 2013